Logo image of INAB

IN8BIO INC (INAB) Stock Price, Quote, News and Overview

NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD

0.169  0 (-1.74%)

After market: 0.1702 +0 (+0.71%)

INAB Quote, Performance and Key Statistics

IN8BIO INC

NASDAQ:INAB (4/30/2025, 8:14:05 PM)

After market: 0.1702 +0 (+0.71%)

0.169

0 (-1.74%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.74
52 Week Low0.13
Market Cap13.73M
Shares81.26M
Float72.48M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO11-12 2020-11-12


INAB short term performance overview.The bars show the price performance of INAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

INAB long term performance overview.The bars show the price performance of INAB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of INAB is 0.169 USD. In the past month the price decreased by -2.14%. In the past year, price decreased by -83.1%.

IN8BIO INC / INAB Daily stock chart

INAB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19 345.13B
AMGN AMGEN INC 14.68 156.41B
GILD GILEAD SCIENCES INC 13.76 132.82B
VRTX VERTEX PHARMACEUTICALS INC 1756.9 130.98B
REGN REGENERON PHARMACEUTICALS 13.51 65.46B
ARGX ARGENX SE - ADR 339.55 39.39B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.24B
ONC BEIGENE LTD-ADR N/A 28.00B
BNTX BIONTECH SE-ADR N/A 25.04B
NTRA NATERA INC N/A 20.40B
SMMT SUMMIT THERAPEUTICS INC N/A 17.79B
BIIB BIOGEN INC 7.35 17.72B

About INAB

Company Profile

INAB logo image IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Company Info

IN8BIO INC

Empire State Building, 350 5Th Avenue, Suite 5330

New York City NEW YORK US

CEO: William Ho

Employees: 39

Company Website: https://www.in8bio.com

Investor Relations: https://investors.in8bio.com/

Phone: 16466006438

IN8BIO INC / INAB FAQ

What is the stock price of IN8BIO INC today?

The current stock price of INAB is 0.169 USD. The price decreased by -1.74% in the last trading session.


What is the ticker symbol for IN8BIO INC stock?

The exchange symbol of IN8BIO INC is INAB and it is listed on the Nasdaq exchange.


On which exchange is INAB stock listed?

INAB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IN8BIO INC stock?

10 analysts have analysed INAB and the average price target is 2.66 USD. This implies a price increase of 1476.78% is expected in the next year compared to the current price of 0.169. Check the IN8BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IN8BIO INC worth?

IN8BIO INC (INAB) has a market capitalization of 13.73M USD. This makes INAB a Nano Cap stock.


How many employees does IN8BIO INC have?

IN8BIO INC (INAB) currently has 39 employees.


What are the support and resistance levels for IN8BIO INC (INAB) stock?

IN8BIO INC (INAB) has a resistance level at 0.18. Check the full technical report for a detailed analysis of INAB support and resistance levels.


Should I buy IN8BIO INC (INAB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IN8BIO INC (INAB) stock pay dividends?

INAB does not pay a dividend.


What is the Price/Earnings (PE) ratio of IN8BIO INC (INAB)?

IN8BIO INC (INAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).


What is the Short Interest ratio of IN8BIO INC (INAB) stock?

The outstanding short interest for IN8BIO INC (INAB) is 0.66% of its float. Check the ownership tab for more information on the INAB short interest.


INAB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

INAB Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to INAB. INAB may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INAB Financial Highlights

Over the last trailing twelve months INAB reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 42.57% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -145.33%
ROE -210.23%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%80.95%
Sales Q2Q%N/A
EPS 1Y (TTM)42.57%
Revenue 1Y (TTM)N/A

INAB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to INAB. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners46.89%
Ins Owners5.71%
Short Float %0.66%
Short Ratio0.33
Analysts
Analysts82
Price Target2.66 (1473.96%)
EPS Next Y63.07%
Revenue Next YearN/A